| Q33613628 | Anthracyclines and the heart |
| Q48146908 | Biochemical changes induced by intravitreally-injected doxorubicin in the iris-ciliary body and lens of the rabbit eye. |
| Q72011914 | Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen |
| Q73866226 | Diagnosis of primary cardiac lymphoma by endomyocardial biopsy |
| Q40304250 | Doxorubicin cardiomyopathy is associated with a decrease in calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model |
| Q36011893 | Doxorubicin-induced cardiomyopathy 17 years after chemotherapy |
| Q28377149 | Doxorubicin-induced late cardiotoxicity: delayed impairment of Ca2+-handling mechanisms in the sarcoplasmic reticulum in the rat |
| Q32118783 | High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity |
| Q68694142 | Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer |
| Q71975481 | Late effects of anthracycline therapy in childhood in relation to the function of the heart at rest and under physical stress |
| Q33180853 | Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy |
| Q67726446 | Long-term sequelae of autologous bone marrow or peripheral stem cell transplantation for lymphoid malignancies |
| Q34466688 | Prognostic role of troponin and natriuretic peptides as biomarkers for deterioration of left ventricular ejection fraction after chemotherapy |
| Q77708592 | Ventricular repolarization time indexes following anthracycline treatment |
| Q74569419 | [Genetics of dilated cardiomyopathy] |